FORM 3
        
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

OMB APPROVAL
OMB Number: 3235-0104
Estimated average burden
hours per response... 0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

Devall Christopher Franklin		 2. Date of Event Requiring Statement (MM/DD/YYYY)
1/1/2023 

 3. Issuer Name and Ticker or Trading Symbol

Dominari Holdings Inc. [DOMH]
(Last)        (First)        (Middle)

ONE ROCKEFELLER PLAZA,, 11TH FLOOR		 4. Relationship of Reporting Person(s) to Issuer (Check all applicable)

_____ Director                          _____ 10% Owner
___X___ Officer (give title below)        _____ Other (specify below)
Chief Operating Officer /
(Street)

NEW YORK, NY 10020      

(City)              (State)              (Zip)
5. If Amendment, Date Original Filed(MM/DD/YYYY)
 

6. Individual or Joint/Group Filing(Check Applicable Line)

_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1.Title of Security
(Instr. 4)		2. Amount of Securities Beneficially Owned
(Instr. 4)		3. Ownership Form: Direct (D) or Indirect (I)
(Instr. 5)		4. Nature of Indirect Beneficial Ownership
(Instr. 5)
Common Stock 13835 (1)D  

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 4)		2. Date Exercisable and Expiration Date
(MM/DD/YYYY)		3. Title and Amount of Securities Underlying Derivative Security
(Instr. 4)		4. Conversion or Exercise Price of Derivative Security5. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 5)		6. Nature of Indirect Beneficial Ownership
(Instr. 5)
Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
(1) On December 16, 2022, the reporting person purchased 3,000 shares of common stock in the public market at an average price of $3.71 per share. On December 19, 2022, the reporting person purchased 1,389 shares of common stock in the public market at $3.599 per share. On December 21, 2022, the reporting person purchased 1,378 shares of common stock in the public market at $3.6599 per share. On July 1, 2022, the reporting person was granted 8,068 shares of restricted stock pursuant to the Company's 2014 Equity Incentive Plan which fully vested on January 1, 2023.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director10% OwnerOfficerOther
Devall Christopher Franklin
ONE ROCKEFELLER PLAZA,
11TH FLOOR
NEW YORK, NY 10020

Chief Operating Officer
Signatures
/s/ Christopher Devall1/6/2023
**Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
*If the form is filed by more than one reporting person, see Instruction 5(b)(v).
**Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note:File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
Grafico Azioni Alkido Pharma (NASDAQ:AIKI)
Storico
Da Nov 2024 a Dic 2024 Clicca qui per i Grafici di Alkido Pharma
Grafico Azioni Alkido Pharma (NASDAQ:AIKI)
Storico
Da Dic 2023 a Dic 2024 Clicca qui per i Grafici di Alkido Pharma